Vicenin-2 inhibits Wnt/β-catenin signaling and induces apoptosis in HT-29 human colon cancer cell line

Dong Yang1,*
Xiling Zhang2,*
Wencun Zhang3
Thamaraiselvan Rengarajan4

1Department of Anorectal Surgery, The First People’s Hospital of Lianyungang, Lianyungang, China; 2Department of Anorectal Surgery, Shaanxi Provincial People’s Hospital, Shaanxi, Xi’an, China; 3Department of Anorectal Surgery, The Fourth Hospital of Yu Lin City, Shaanxi Province, China; 4Scigen Research and Innovation, Periyar Technology Business Incubator, Thanjavur, Tamil Nadu, India

*These authors contributed equally to this work.

Background: Colorectal cancer (CRC) is among the highest prevailing cancers in the whole world, especially in western countries. For a diverse range of reasons, patients prefer naturally occurring dietary substances over synthetic agents to prevent cancer. Vicenin-2 is largely available in a medicinal plant Ocimum sanctum and is an apigenin form, 6,8-di-C-glucoside, which has been reported to have a range of pharmacological values which includes antioxidant, hepatoprotective, anti-inflammatory and anti-cancer. This study aimed to analyze the anti-proliferative effect of Vicenin-2 on human colon cancer cells via the Wnt/β-catenin signaling inhibition.

Methods: MTT assay was used to assess the cell viability at different concentrations and time points. Vicenin-2 at a concentration of 50 µM (IC50) decreased the phosphorylated (inactive) glycogen synthase kinase-3β, cyclin D1, and non-p-β-catenin expressions in HT-29 cells, which were evidenced through western blot analysis.

Results: Further, Vicenin-2 reduced the T-cell factor (TCF)/Leukocyte erythroid factor (LEF) reporter activity in HT-29 cells. Vicenin-2 also promoted substantial cell cycle arrest at the G0/M phase of HT-29 cells, as well induced apoptosis in HT-29 cells, as revealed through flow cytometric analysis. Furthermore, immunoblot analysis showed that Vicenin-2 treatment enhanced the expression of Cytochrome C, Bax and caspase-3 whereas suppressed the Bcl-2 expression.

Conclusion: Together, these results revealed that Vicenin-2 can act as a potent inhibitor of HT-29 cell proliferation and can be used as an agent against CRC.

Keywords: colorectal cancer, Vicenin-2, β-catenin, apoptosis, caspase-3

Introduction

Colorectal cancer (CRC) is one of the highest prevailing cancers worldwide, especially in the western countries. Recent statistics state that, there are 6,94,000 CRC-related deaths and 1.36 million new CRC cases reported annually worldwide.1,2 Once the CRC is diagnosed, treatment at early stage is remarkable, and at metastasis stage, 5-year survival rate of the CRC patients is only 12.5%.3 Currently, there is a hike in the number of studies and research interest in identifying novel sources of bioactive compounds for colon cancer prevention.4,5 Especially, naturally occurring bioactive compounds from a dietary source are of substantial interest for the prevention of CRC.6

The development of CRC is critically influenced by the Wnt/β-catenin signaling pathway.7 β-Catenin cooperates with glycogen synthase kinase (GSK)-3β and adenomatous polyposis coli (APC) forming a complex, which is degraded by the ubiquitination process under normal circumstances. During CRC, APC is mutated and thus becomes unable to bind with β-catenin and GSK-3β, causing an accumulation of β-catenin in the cytosol, which later translocates into the nucleus.8,9 β-Catenin binds
with T-cell factor (TCF)/leukocyte erythroid factor (LEF) in the nucleus and eventually transcribes downstream target genes such as C-Myc and cyclin-D1, which are responsible for cell proliferation. Due to these factors, Wnt/β-catenin signaling has become the crucial target to treat CRC.

Vicenin-2 is a nontoxic flavonoid from the herb Ocimum sanctum Linn and Moringa oleifera, which are widely available in the region of Southern Asia. Vicenin-2 has been reported to possess many pharmacological properties that include antioxidant, hepatoprotective, antiinflammatory, and anticancer effects. Vicenin-2 inhibits angiogenesis and decreases the expression of vascular endothelial growth factor in prostate cancer, and it was proven to be effectively absorbed after oral administration in preclinical models, which was correlated with tumor regression.

**Materials and methods**

**Chemicals**

Vicenin-2, β-actin antibody, and DMEM were obtained from Sigma-Aldrich Co., St Louis, MO, USA. Polyvinylidene difluoride (PVDF) membrane was obtained from Millipore, Burlington, MA, USA. Fetal bovine serum (FBS), trypsin-EDTA, antibiotics–antimycotics and PBS were obtained from Thermo Fisher Scientific, Waltham, MA, USA. Primary antibodies against phosphorylated (inactive) GSK-3β, cyclin D1, and non-p-β-catenin were obtained from Santa Cruz Biotechnology Inc., Dallas, TX, USA and Cell Signaling (Danvers, MA, USA). The secondary antibodies, horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG and rabbit anti-mouse IgG were purchased from Dako Denmark A/S, Glostrup, Denmark. Enhanced chemiluminescence kit was obtained from Thermo Fisher Scientific. All the chemicals used in this study were of highest quality and analytical grade.

**Cell line and culture conditions**

Human colon cancer cell line HT-29 was obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA) and was maintained in DMEM, supplemented with 1% nonessential amino acid, 10% v/v FBS, 1% L-glutamine (Thermo Fisher Scientific), and 100 µg/mL penicillin/streptomycin (Sigma-Aldrich Co.) in a humidified atmosphere with 5% CO₂ at 37°C. The cells were grown in T75 culture flasks comprising DMEM added with 1% antibiotics (100 µg/mL of streptomycin and 100 µg/mL of penicillin) and 10% FBS. The cells were conserved in a humidified atmosphere with 5% CO₂ at 37°C. The cells were trypsinized and passaged prior to achieving confluence. The cells were then collected for analyses, including immunoblotting analysis, cell viability, and flow cytometric analysis.

For the treatments of Vicenin-2 (Stock solution of 1 M of Vicenin-2 in DMSO), cells were starved for 24 hours in a serum-free DMEM and incubated with Vicenin-2 at different concentrations (0, 3.12, 6.24, 12.5, 25, 50, 100, and 150 µM) for 24 and 48 hours in a serum-free DMEM.

**Cell viability**

MTT assay was used to determine cell viability as described previously. Briefly, cells were seeded at a density of 1 × 10⁴ cells/well in a 24-well plate and cultured in a serum-free DMEM for 16 hours. The cells were then treated with Vicenin-2 in serial concentrations (0, 3.12, 6.24, 12.5, 25, 50, 100, and 150 µM) for 24 or 48 hours. Each concentration treatment was performed in triplicate. The medium was aspirated after treatment, and PBS was used to wash the cells. Subsequently, the cells were incubated for 4 hours with MTT solution (5 mg/mL). The supernatant formed was removed, and the isopropanol was used to solubilize the formazan and was measured spectrophotometrically at 570 nm. The percentage of viable cells was calculated in contrast to untreated cells. Percentage viability was calculated using the following formula:

\[
\text{OD}_{\text{sample}} \times 100\% = \frac{\text{OD}_{\text{sample}}}{\text{OD}_{\text{control}}} \times 100\% .
\]

**Confocal microscopic analysis**

Cells were treated with and without Vicenin-2 for 3 and 6 hours and later fixed with 4% paraformaldehyde. Cells were then permeabilized with 0.3% Triton X-100, incubated with goat serum, and then stained with anti-non-p-β-catenin antibody (Abcam, Cambridge, MA, USA, 1:200 dilutions) at 4°C overnight. The cells were then incubated with secondary antibody goat anti-rabbit IgG (1:500 dilutions) for 1 hour at 37°C and 1 µM DAPI (Southern Biotech, Birmingham, AL, USA) for 10 minutes. The samples were then examined under a confocal microscope.

**Determination of cell cycle distribution**

Flow cytometry was used to analyze the cell cycle distribution. Cells were collected and fixed with 1 mL of ice cold 70% ethanol after treatment with Vicenin-2, incubated at −20°C for at least 24 hours, and centrifuged at 380 × g at room temperature for 5 minutes. Cell pellets obtained were treated with 1 mL of cold staining solution comprising 20 µg/mL
RNase A, 20 μg/mL propidium iodide, and 1% Triton X-100, and then incubated in dark for 15 minutes at room temperature. The samples were subsequently analyzed using FACS Calibur system (version 2.0; BD Biosciences, San Jose, CA, USA) using Cell Quest software. The results represented were of at least three independent experiments.

**Luciferase reporter assay**

The firefly luciferase reporter plasmid M50 super 8×TOPflash or its control counterpart M51 super 8×FOPflash was used to transiently transfect the HT-29 cells. X-tremeGene HP DNA transfection agent (Hoffmann-La Roche Ltd., Basel, Switzerland) was used to transfect the HT-29 cells. Super TOPflash has seven consensus TCF/LEF-binding sites upstream of a minimal thymidine kinase promoter driving the expression of luciferase. TCF/LEF binding sites are mutated in Super FOPflash. The cells were cotransfected using sea pansy Renilla pRL-SV40 purchased from Addgene (Cambridge, MA, USA), where expression of luciferase was driven by the SV40 promoter. The cells were treated with vehicle, Vicenin-2, or lithium chloride (LiCl) 48 hours after transfection, and activity of luciferase reporter was examined via the Dual-Glo Luciferase Assay System (Promega Corporation, Fitchburg, WI, USA). The activity of firefly luciferase was normalized to the activity value of each sample from Renilla luciferase.

**Protein extraction and Western blot analysis**

HT-29 cells were cultured in 100 mm culture plates (1×10⁶ per plate) containing growth medium. The cells (70%–80% confluent) were rinsed twice after 24 hours with serum-free medium and then incubated in 5 mL serum-free medium to starve the cells. The cells were treated with dimethyl sulfoxide (vehicle) and 50 μM of Vicenin-2 after starvation. After the appropriate treatment time, the cells were lysed in radio-immunoprecipitation assay buffer containing phosphatase inhibitor cocktail and 1×protease. Then, the cells were sonicated for 30 minutes at 4°C, and the homogenate was centrifuged for 10 minutes at 14,000 × g to collect the supernatant, which was stored at −70°C for further analysis. The protein concentration was quantitated according to Lowry’s method. The cell lysates (40 μg) were electrophoresed in a 12% sodium dodecyl sulfate polyacrylamide gel (SDS-PAGE), which was then transferred onto PVDF membranes. The membranes were incubated along with primary antibodies (GSK-3β, p-GSK-3β, Bcl-2, Bax, Cytochrome C, cyclin D1, non-p-β-catenin, and caspase 3) and added into tris-buffered saline. The membranes were rinsed and incubated with HRP-conjugated goat anti-rabbit IgG (1:5,000 dilutions) and rabbit anti-mouse IgG (1:5,000 dilutions) secondary antibodies. The bands were visualized on autoradiographic films with the SuperSignal West-Pico Kit (Pierce, Rockford, IL, USA) and quantified by densitometry with ImageJ software (NIH, Bethesda, MD, USA).

**Statistical analysis**

All data were expressed as mean±SD. Statistical analysis was performed using windows Statistical Package for Students version 7.5 to perform one-way analysis of variance (ANOVA) followed by Tukey’s multiple comparisons test. P-values <0.05 (P<0.05) were regarded as significant.

**Results**

**Vicenin-2 decreased the cell viability in HT-29 colon cancer cells**

HT-29 cells were treated with different concentrations of Vicenin-2 (0–150 μM) for 24 and 48 hours. MTT assay was performed to analyze the cell viability, and the results are shown in Figure 1. Increasing concentrations of Vicenin-2 treatment gradually decreased the percentage of cell survival. From these results, the IC₅₀ value of Vicenin-2 was calculated to be 50 μM. Therefore, we chose this concentration to perform further analysis to identify the mechanism of action of Vicenin-2.

**Vicenin-2 reduced the TCF/LEF reporter activity**

Administration of Vicenin-2 at the dose of 50 μM concentration significantly reduced the TCF/LEF binding activity of HT-29 cells (%)

![Figure 1](https://www.dovepress.com/)

**Notes:** The HT-29 colon cancer cells were treated with the doses of 0, 3.12, 6.24, 12.5, 25, 50, 100, and 150 μM concentrations of Vicenin-2. After the treatment, the cells were incubated with MTT solution for 4 hours. Vicenin-2 showed inhibition of HT-29 cell growth at the IC₅₀ of 50 μM. "*" denotes the statistical difference at P<0.01. "**" denotes the statistical difference at P<0.05.
in luciferase TCF/LEF reporter assay in a time-dependent manner (Figure 2).

**Effect of Vicenin-2 on cyclin D1 and non-p-β-catenin expressions**

Western blot analysis was performed to evaluate the effects of Vicenin-2 on the non-p-β-catenin (92 kDa) and its downstream target cyclin D1 (36 kDa) expressions. Total cell lysates of HT-29 cells were treated with or without Vicenin-2 for the indicated time and were analyzed using SDS-PAGE electrophoresis, which were subsequently immunoblotted with antisera against β-actin, non-p-β-catenin, and cyclin D1. The results are shown in Figure 3A. The localization of non-p-β-catenin was evidenced by the confocal microscopic

![Figure 3A](image)

**Figure 3A** Vicenin-2 inhibits the expression and activation of Wnt/β-catenin signaling.

Notes: (A) Western blot analysis of Wnt/β-catenin signaling proteins such as non-p-β-catenin, total-β-catenin, and cyclin D1. (B) The densitometric quantification of respective Western blot by ImageJ software (NIH). “**” denotes the statistical difference at \( P < 0.05 \). (C) The nuclear localization of non-p-β-catenin was analyzed by a confocal microscope. Vicenin-2 treatment time dependently reduces the nuclear accumulation of non-p-β-catenin.
Drug Design, Development and Therapy 2018:12

Vicenin-2 inhibits colon cancer cells

The effect of Vicenin-2 was clearly indicated by confocal microscopic analysis (Figure 3).

**Effect of Vicenin-2 on GSK-3β in degradation of β-catenin**

In order to ascertain that the downregulation of non-p-β-catenin was mediated by GSK-3β, HT-29 cells were treated with Vicenin-2 at different time intervals (Figure 3B) or in combination with LiCl, which is a GSK-3β inhibitor. Western blot analysis was used to determine the expressions of total p-GSK-3β, GSK-3β, and non-p-β-catenin. Vicenin-2 treatment alone reduced the expressions of total p-GSK-3β and non-p-β-catenin in HT-29 cells but did not show any difference in total GSK-3β (Figure 4A). Combination treatment of LiCl/Vicenin-2 showed no change in the expression of non-p-β-catenin (Figure 4B).

**Vicenin-2 inhibits proliferation and causes G₂M phase arrest through repression of cyclins**

The effect of Vicenin-2 on cell cycle of HT-29 cells is represented in Figure 5 (A and B). Growth inhibitory effect of Vicenin-2 was due to cell cycle arrest, which was evidenced through accumulation of cells at the G₂/M phase. Flow cytometric analysis was used to determine the effect of Vicenin-2 on the distribution of cell cycle. The results of analysis showed that the HT-29 cells were accumulated at the G₂/M phase upon treatment with Vicenin-2 at both 24 and 48 hours. The percentages of cell population at the G₂/M phase were increased by 28.7% at 24 hours and 74.06% at 48 hours due to Vicenin-2 treatment.

**Vicenin-2 induces apoptosis by modulating the expressions of Bax, Bcl-2, Cytochrome C, and caspase-3**

Since administration of Vicenin-2 was able to inhibit the Wnt/β-catenin signaling pathway and arrest the cell cycle at the G₂/M phase, we analyzed the effect of Vicenin-2 on the induction of apoptosis and the underlying molecular mechanism (Figure 6). First, the effect of Vicenin-2 on annexin-V-FITC expression by flow cytometry in HT-29 cells was analyzed. It was found that Vicenin-2 treatment (50 µM) at 24 and 48 hours showed increased early apoptosis (Figure 6A). The status of apoptosis modulators such as Cytochrome C, Bcl-2, Bax, and caspase-3 was evaluated using Western blot analysis (Figure 6B). Administration of Vicenin-2, time dependently elevated the expressions of Cytochrome C, Bax, and caspase-3 and declined the anti-apoptotic Bcl-2 expression (Figure 6C).

---

**Figure 4** Effect of Vicenin-2 on the expression of p-GSK-3β.

**Notes:** (A) Western blot expressions of p-GSK-3β and T-GSK-3β. (B) The densitometric quantification of p-GSK-3β and T-GSK-3β by ImageJ software (NIH). *p* denotes the statistical difference at *P*<0.05. (C) To confirm the inhibition of non-p-β-catenin by Vicenin-2 was mediated through GSK-3β, the cells were incubated with Vicenin-2 and LiCl (GSK-3β inhibitor). (D) The densitometric quantification of non-p-β-catenin by ImageJ software (NIH). *p* denotes the statistical difference at *P*<0.05.

**Abbreviations:** GSK, glycogen synthase kinase; LiCl, lithium chloride.
Figure 5 Vicenin-2 arrests the cell cycle at the G2/M phase.
Notes: (A) The effect of Vicenin-2 on cell cycle distribution was analyzed by flow cytometry. (B) The experiment was done in triplicate and is represented as a graph. "*" denotes the statistical difference at P<0.05.

Figure 6 Vicenin-2 induces apoptosis in HT-29 cells by modulating the expressions of Cytochrome C, Bax, Bcl-2, and caspase-3.
Notes: (A) Vicenin-2 induces apoptosis by increasing the Annexin V-FITC expression confirmed by flow cytometry. (B) Western blot analysis of Cytochrome C, Bax, Bcl-2, and caspase-3. (C) The densitometric quantification of respective Western blot by ImageJ software (NIH). "**" denotes the statistical difference at P<0.05.
**Discussion**

CRC is the third most common cancer causing death in the world, demonstrating that current therapies are unable to eradicate certain cancer cells effectively.\(^{14,15}\) The CRC mortality rate is high due to the tendency for early metastasis and high resistance to chemotherapy and radiation.\(^{10,15}\) Previous reports have confirmed the existence of cytotoxic compounds in different plants that show potential anticancer effects in various cancer cells.\(^{16–19}\) Vicenin-2 belongs to the C-glycoside flavonoid family, which is abundantly found in the *O. sanctum* Linn and *M. oleifera* plants.\(^{20}\)

In this study, the effects of Vicenin-2 on cell proliferation, cell cycle distribution, and apoptosis induction were evaluated in HT-29 human CRC cells. Results of this study indicated that Vicenin-2 is able to decrease proliferation of HT-29 cancer cells in a time- and concentration-dependent manner. Results of MTT assay showed that the IC\(_50\) of Vicenin-2 has significant cytotoxic effects on HT-29 cancer cells. The data also indicated that Vicenin-2 can enhance the anticancer effects at lower concentration, which in turn decreases the side effects associated with Vicenin-2 on normal cells. It was well accepted that most conventional chemotherapeutic agents target rapidly dividing tumor cells and therefore have minor effects on the slow dividing and quiescent CRCs.\(^{21,22}\) Furthermore, the cell cycle arrest followed by apoptosis induction in tumor cells after treatment with chemotherapeutic agents is the main efficient strategy to prevent the uncontrolled cell proliferation of cancer cells. The flow cytometric analysis of cell cycle results further support that a high percentage of HT-29 cancer cells was arrested in the G\(_{2}/M\) phase due to treatment with Vicenin-2, which is consistent with the results of other anticancer drugs.\(^{23,24}\) It has been reported that Vicenin-2 induces G\(_{2}/M\) phase accumulation due to the enhanced level of cyclin B and decreased level of cyclin D1.\(^{25}\)

Wnt/\(\beta\)-catenin signaling plays an important role in the pathogenesis of CRC, and drugs that target the \(\beta\)-catenin pathway potentially reduce the tumor growth.\(^{26–28}\) Accumulation of free \(\beta\)-catenin in the cytosol due to activation of GSK-3\(\beta\) eventually translocates into the nucleus, thus trans-activating several target genes associated in tumorigenesis.\(^{29}\) Especially, the plant products effectively inhibit the \(\beta\)-catenin expression and inhibit the tumor formation. Emodin is a type of anthraquinone active substance that inhibits CRC cell invasion and migration by suppressing epithelial mesenchymal transition via the Wnt/\(\beta\)-catenin pathway.\(^{30}\) Curcumin is known as yellow gold, and it suppresses the CRC proliferation by inhibiting Wnt/\(\beta\)-Catenin pathways via miR-130a (Dou et al\(^ {15}\)). *Telectadium dongnaiense* and its constituents inhibit the CRC cell proliferation by inhibiting the Wnt/\(\beta\)-catenin signaling pathway. Consistent with the previous findings, treatment with Vicenin-2 downregulated the non-p-\(\beta\)-catenin along with a decrease in phosphorylation of GSK-3\(\beta\) (Kim et al\(^ {12}\)). In addition, the effect of Vicenin-2 on TCF/LEF reporter assay revealed that Vicenin-2 reduced the binding of non-p-\(\beta\)-catenin to TCF/LEF promoter. These results are also favorable to suggest Vicenin-2 as a potential therapeutic candidate for reversing multidrug resistance of cancer cells due to its ability to inhibit Wnt/\(\beta\)-catenin signaling.\(^ {30}\)

**Conclusion**

The present study demonstrated that Vicenin-2 inhibited cell viability, induced apoptosis, and led to cell-cycle arrest in HT-29 cells. Vicenin-2 inhibits the \(\beta\)-catenin expression and nuclear accumulation. In addition, this effect was mediated through the suppression of p-GSK-3\(\beta\). Additionally, the expressions of apoptosis-associated proteins Bax, Cytochrome C, and caspase-3 were increased, whereas that of Bcl-2 was decreased following treatment with Vicenin-2. It was already reported that Vicenin-2 induces apoptosis in prostate cancer cells through the activation of caspase-3.\(^ {25}\) Therefore, the Wnt/\(\beta\)-catenin pathway signaling axis might be a potent target for the novel treatment strategies of CRC. This study indicated that Vicenin-2 could play a beneficial role in the comprehensive clinical treatment of CRC.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


